View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Michiel Declercq
  • Michiel Declercq

Colruyt 1H25/26 disappoints, outlook reiterated, but with caution

Although Colruyt already flagged during the AGM that the operating result in 1H25/26 would be lower, the -15.8% EBIT decline in 1H25/26 to € 213m came in below our estimates (kbcse: € 230m). While Colruyt still banks on a stable operating result and net profit for FY25/26, the group did highlight that the situation has become more complicated following the ongoing price and promo pressure, increased Sunday openings, abolition of the mandatory closing day and uneven level playing field in labour ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Colruyt: Guidance reiterated despite weaker-than-expected 1H25/26. Dutch Pension Buyouts: Regulator DNB's view, c.€7bn so far, insurers at 15% market share now. OCI: Dutch investor association VEB and other shareholders take legal action to block Orascom merger. Proximus: CFO Mark Reid to leave Proximus by end of January 2026. Staffing Sector: US temp volume YoY declined vs October; NFP jobs beat expectations. Var Energy: Boosting production bodes well for years to come. Events Calendar

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Arcadis: New CEO, new wind?. Colruyt: Job protection plan approved by authorities. Colruyt: Preview 1H25/26. IMCD: New CFO announced.

Hilde Van Boxstael ... (+8)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aegon: CMD: UK up for sale (+) US legacy transaction (+), its cost (- -), targets in line (=). Kinepolis: Poor November box office in US/Canada and France attendance. MICC: Golden ice.

Floridienne S.A.: 1 director

A director at Floridienne S.A. bought 42 shares at 600.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Jacob Mekhael ... (+2)
  • Jacob Mekhael
  • Thibault Leneeuw
Jacob Mekhael
  • Jacob Mekhael

MaaT Pharma Final Xervyteg phase 3 data confirm strong survival outcom...

MaaT reported the final results from the phase 3 (ARES) trial of Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD at the American Society of Hematology (ASH) conference, being held 6-9 December 2025. The final OS results from the phase 3 (ARES) trial of MaaT013 coming in at 54% at 1 year confirm the previously reported 54% probability of survival that was shared with the topline readout in January 2025. We believe this brings a significant benefit vs. the 15% 1-year OS reported...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Peer Kroger 3Q25 results Kinepolis: Warner and Netflix enter exclusive deal negotiations UCB: FY25 guidance raised on Bimzelx's exceptional performance

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Basic-Fit: Highlights and calculations on the back of Clever Fit analyst meeting. Colruyt: Exiting France after closing its last five stores

Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Wim Hoste
  • Wim Lewi
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Adecco: Capital Markets Day 2025; share price background. Ascencio: Results in line, solid recovery in occupancy, dividend up 3.5%. Colruyt: Conflicts between Intermarché Belgium and its franchisees. Theon International: Continued growth in Thermal

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch